SPONSOR
The First Affiliated Hospital of Xiamen University
Total Trials
10
Recruiting
10
Phases
Phase 2, EARLY_Phase 1, Phase 1
Conditions studied: Leukemia, Myeloid, AcuteAML Stage, AdultDry Eye DiseaseUmbilical Cord Mesenchymal Stem Cell-derived Small Extracellular VesiclesAcute Myeloid LeukemiaRelapseRefractory AMLPituitary NeoplasmsNephrotic SyndromeRituximab
The First Affiliated Hospital of Xiamen University is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Leukemia, Myeloid, Acute, AML Stage, Adult, Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles.
The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital of Xiamen University
How many clinical trials has The First Affiliated Hospital of Xiamen University sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by The First Affiliated Hospital of Xiamen University, of which 10 are actively recruiting participants. These trials cover conditions including Leukemia, Myeloid, Acute, AML Stage, Adult, Dry Eye Disease. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital of Xiamen University research focus on?
The First Affiliated Hospital of Xiamen University clinical trials span Leukemia, Myeloid, Acute, AML Stage, Adult, Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles, Acute Myeloid Leukemia, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital of Xiamen University clinical trial?
To participate in a The First Affiliated Hospital of Xiamen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital of Xiamen University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital of Xiamen University
NCT05603884 Phase 2
Recruiting
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
NCT07623382 EARLY_Phase 1
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
Dry Eye Disease
NCT06737523 Phase 1
Recruiting
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
Acute Myeloid Leukemia
NCT06282224
Recruiting
Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery
Pituitary Neoplasms
NCT06530004
Recruiting
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Nephrotic Syndrome
NCT04416165
Recruiting
Comparison of FDG and FAPI in Patients With Various Types of Cancer
Tumor, Solid
NCT07035938
Recruiting
T-cell Developmental Status in Patients With Malignant Hematological Tumors
Hematologic Malignancy
NCT07547930 Phase 2
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease, TED
NCT05873777
Recruiting
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
SSTR2
NCT06158399 Phase 2
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
DLBCL - Diffuse Large B Cell Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology